Perspective Therapeutics presented updated interim Phase 1/2a clinical trial data for its lead radiopharmaceutical candidate [212Pb]VMT-α-NET at the AACR 2026 Annual Meeting, showing continued safety and efficacy signals.
Key takeaways
Updated safety data from 64 treated patients showed no dose-limiting toxicities, treatment-related discontinuations, serious renal complications, or clinically significant myelosuppression.
Efficacy analysis of 25 patients in Cohorts 1 and 2 showed 72% progression-free survival and a 43% objective response rate in Cohort 2 patients.
The company plans to submit a clinical evidence package for regulatory engagement in 2026 and expects additional efficacy data from later cohorts later this year.
The candidate is described as potentially first-in-class 212Pb-radiopharmaceutical therapy targeting SSTR2-expressing neuroendocrine tumors.